ITX 401
Alternative Names: ITX-401Latest Information Update: 25 Apr 2023
At a glance
- Originator Immune Therapeutics
- Developer Biostax
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 27 Jul 2022 No development reported - Phase-II for Pancreatic cancer in USA (unspecified route)
- 20 Mar 2020 Phase-II clinical trials in Pancreatic cancer in USA (unspecified route)
- 20 Mar 2020 Immune Therapeutics announces intention to submit a request for Type C meeting to US FDA for phase III program for Pancreatic cancer in April 2020